Literature DB >> 11164485

Evaluation of hepatitis C virus RNA RT/PCR qualitative and quantitative second generation assays.

F J Castro1, S Sauleda, J I Esteban, L Viladomiu, M Martell, E Dragon, R Esteban, J Guardia.   

Abstract

Hepatitis C virus (HCV) RNA qualitative and quantitative second generation assays (Amplicor HCV v2.0 and Amplicor HCV Monitor v2.0, respectively) were evaluated by testing serum samples from 132 blood donors anti-HCV positive HCV RNA negative by first generation qualitative assay and 326 viremic patients. An HCV RNA transcript was synthesized and ten-fold dilutions were used to assess sensitivity. Second generation assays were one log more sensitive than their respective first generation tests (10(2) copies per ml vs. 10(3) for the qualitative tests; 10(3) copies per ml vs. 10(4) for the quantitative tests). From the 132 anti-HCV positive RNA negative subjects, 6 (5%) were positive by Amplicor v2.0. Quantification figures by Monitor v2.0 were similar in genotypes 1, 2 and 3, whereas Monitor 1.0 values were higher in genotype 1 than in genotype 2 or 3. In 114 patients, branched-DNA v2.0 obtained higher values than Monitor v2.0 and Monitor v1.0 (6.6+/-0.6 log RNA copies per ml, 6.4+/-0.6, and 5.3+/-0.7, respectively, P<0.001). HCV RNA qualitative and quantitative second generation assays are more sensitive and genotype independent than first generation assays.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11164485     DOI: 10.1016/s0166-0934(00)00243-3

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  2 in total

1.  Increased sensitivity of the Roche COBAS AMPLICOR HCV test, version 2.0, using modified extraction techniques.

Authors:  Michael Stuart Forman; Alexandra Valsamakis
Journal:  J Mol Diagn       Date:  2004-08       Impact factor: 5.568

2.  Development of a TaqMan assay for the six major genotypes of hepatitis C virus: comparison with commercial assays.

Authors:  Ronald E Engle; Rodney S Russell; Robert H Purcell; Jens Bukh
Journal:  J Med Virol       Date:  2008-01       Impact factor: 2.327

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.